Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism Accompany Melanocyte Neoplasia Progression in Zebrafish.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 05 2019
Historique:
received: 06 08 2018
revised: 23 01 2019
accepted: 04 03 2019
pubmed: 14 3 2019
medline: 8 2 2020
entrez: 14 3 2019
Statut: ppublish

Résumé

Alterations in lipid metabolism in cancer cells impact cell structure, signaling, and energy metabolism, making lipid metabolism a potential diagnostic marker and therapeutic target. In this study, we combined PET, desorption electrospray ionization-mass spectrometry (DESI-MS), nonimaging MS, and transcriptomic analyses to interrogate changes in lipid metabolism in a transgenic zebrafish model of oncogenic RAS-driven melanocyte neoplasia progression. Exogenous fatty acid uptake was detected in melanoma tumor nodules by PET using the palmitic acid surrogate tracer 14(R,S)-18F-fluoro-6-thia-heptadecanoic acid ([18F]-FTHA), consistent with upregulation of genes associated with fatty acid uptake found through microarray analysis. DESI-MS imaging revealed that FTHA uptake in tumors was heterogeneous. Transcriptome and lipidome analyses further highlighted dysregulation of glycerophospholipid pathways in melanoma tumor nodules, including increased abundance of phosphatidyl ethanolamine and phosphatidyl choline species, corroborated by DESI-MS, which again revealed heterogeneous phospholipid composition in tumors. Overexpression of the gene encoding lipoprotein lipase (LPL), which was upregulated in zebrafish melanocyte tumor nodules and expressed in the majority of human melanomas, accelerated progression of oncogenic RAS-driven melanocyte neoplasia in zebrafish. Depletion or antagonism of LPL suppressed human melanoma cell growth; this required simultaneous fatty acid synthase (FASN) inhibition when FASN expression was also elevated. Collectively, our findings implicate fatty acid acquisition as a possible therapeutic target in melanoma, and the methods we developed for monitoring fatty acid uptake have potential for diagnosis, patient stratification, and monitoring pharmacologic response. SIGNIFICANCE: These findings demonstrate the translational potential of monitoring fatty acid uptake and identify lipoprotein lipase as a potential therapeutic target in melanoma.

Identifiants

pubmed: 30862716
pii: 0008-5472.CAN-18-2409
doi: 10.1158/0008-5472.CAN-18-2409
doi:

Substances chimiques

Fatty Acids 0
Glycerophospholipids 0
Microphthalmia-Associated Transcription Factor 0
Zebrafish Proteins 0
mitfa protein, zebrafish 0
Fatty Acid Synthases EC 2.3.1.85
Lipoprotein Lipase EC 3.1.1.34
ras Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2136-2151

Subventions

Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M017702/1
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C8742/A18097
Pays : United Kingdom

Informations de copyright

©2019 American Association for Cancer Research.

Auteurs

Fiona Henderson (F)

Wolfson Molecular Imaging Centre, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.
Division of Pharmacy and Optometry, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Hannah R Johnston (HR)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Andrew P Badrock (AP)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Emrys A Jones (EA)

Waters Corporation, Wilmslow, United Kingdom.

Duncan Forster (D)

Wolfson Molecular Imaging Centre, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Raghavendar T Nagaraju (RT)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Christos Evangelou (C)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Jivko Kamarashev (J)

Department of Dermatology and Allergy, UniversitätsSpital Zürich, Zürich, Switzerland.

Michael Green (M)

Wolfson Molecular Imaging Centre, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Michael Fairclough (M)

Wolfson Molecular Imaging Centre, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Irene Barinaga-Rementeria Ramirez (IB)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Shuning He (S)

Institute of Biology, Leiden University, Leiden, the Netherlands.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

B Ewa Snaar-Jagalska (BE)

Institute of Biology, Leiden University, Leiden, the Netherlands.

Katherine Hollywood (K)

Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.

Warwick B Dunn (WB)

Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.
School of Biosciences, Institute of Metabolism and Systems Research and Phenome Centre, University of Birmingham, Edgbaston, Birmingham, United Kingdom.

Herman P Spaink (HP)

Institute of Biology, Leiden University, Leiden, the Netherlands.

Michael P Smith (MP)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Paul Lorigan (P)

Division of Cancer Sciences, School of Medical Sciences, Department of Medical Oncology, The Christie NHS Foundation Trust, The University of Manchester, Withington, Manchester, United Kingdom.

Emmanuelle Claude (E)

Waters Corporation, Wilmslow, United Kingdom.

Kaye J Williams (KJ)

Division of Pharmacy and Optometry, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom.

Adam W McMahon (AW)

Wolfson Molecular Imaging Centre, Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom. adam.hurlstone@manchester.ac.uk adam.mcmahon@manchester.ac.uk.

Adam Hurlstone (A)

Division of Cancer Sciences, School of Medical Sciences, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom. adam.hurlstone@manchester.ac.uk adam.mcmahon@manchester.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH